Table 2.
Treatment response
| Baseline | Posttreatment | ||||
|---|---|---|---|---|---|
| Patient | Hemodynamic characteristics | MIF (ng/mL) | PAH therapy | Hemodynamic characteristics | MIF (ng/mL) |
| Incident cases before and after initiation of PAH therapy | |||||
| 1 | mPAP: 55 mmHg; PVR: 750 dynes˙s˙cm−5; CO: 5.3 L/min | 120.00 | PDE5I and ERA | mPAP: 44 mmHg; PVR: 273 dynes˙s˙cm−5; CO: 7.0 L/min | 75.08 |
| 2 | mPAP: 51 mmHg; PVR: 629 dynes˙s˙cm−5; CO: 5.9 L/min | 65.30 | PDE5I and INH PGI2 | mPAP: 34 mmHg; PVR: 194 dynes˙s˙cm−5; CO: 8.2 L/min | 63.01 |
| 3 | mPAP: 40 mmHg; PVR: 364 dynes˙s˙cm−5; CO: 5.5 L/min | 42.80 | PDE5I (noncompliant) | mPAP: 42 mmHg; PVR: 408 dynes˙s˙cm−5; CO: 5.1 L/min | 58.60 |
| 4 | mPAP: 44 mmHg; PVR: 278 dynes˙s˙cm−5; CO: 8.3 L/min | 33.94 | PDE5I | mPAP: 43 mmHg; PVR: 270 dynes˙s˙cm−5; CO: 7.1 L/min | 21.92 |
| 5 | mPAP: 49 mmHg; PVR: 614 dynes˙s˙cm−5; CO: 5.0 L/min | 72.70 | PDE5I and INH PGI2 | mPAP: 32 mmHg; PVR: 219 dynes˙s˙cm−5; CO: 7.0 L/min | 38.84 |
| 6 | mPAP: 46 mmHg; PVR: 465 dynes˙s˙cm−5; CO: 6.9 L/min | 13.01 | ERA and PDE5I | mPAP: 30 mmHg; PVR: 214 dynes˙s˙cm−5; CO: 8.6 L/min | 15.21 |
| Prevalent cases before and after uptitration of PAH therapy | |||||
| 7 | mPAP: 31 mmHg; PVR: 317 dynes˙s˙cm−5; CO: 5.3 L/min on PDE5I and INH PGI2 | 46.68 | PDE5I, ERA, and INH PGI2 | mPAP: 34 mmHg; PVR: 171 dynes˙s˙cm−5; CO: 8.0 L/min | 30.46 |
| 8 | mPAP: 31 mmHg; PVR: 233 dynes˙s˙cm−5; CO: 7.9 L/min on PDE5I | 38.48 | PDE5I and ERA | mPAP: 31 mmHg; PVR: 159 dynes˙s˙cm−5; CO: 11.1 L/min | 56.81 |
Note
Pulmonary hemodynamic characteristics and central venous macrophage migration inhibitory factor (MIF) levels before and after initiation or uptitration of pulmonary arterial hypertension therapy. CO: cardiac output; ERA: endothelin receptor antagonist; INH: inhaled; mPAP: mean pulmonary arterial pressure; PAH: pulmonary arterial hypertension; PDE5I: phosphodiesterase 5 inhibitor; PGI2: prostacyclin; PVR: pulmonary vascular resistance.